Randomized clinical trials have already demonstrated the benefit of combining VEGF targeting agents with chemotherapy in stage IV CRC.[45, 46] Ganetespib also inhibits epithelial to mesenchymal transition (EMT) in CRC cell lines [35]. The gene discussed is VEGFA; the disease is colorectal carcinoma.